CA Patent

CA2338855A1 — Indole spla2 inhibitors

Assigned to Eli Lilly and Co · Expires 2000-02-17 · 26y expired

What this patent protects

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

USPTO Abstract

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Drugs covered by this patent

Patent Metadata

Patent number
CA2338855A1
Jurisdiction
CA
Classification
—
Expires
2000-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.